7Baggers
Quarterly
Annual
    Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2020-12-31 2020-09-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 
      
    		                                       
      cash flows from operating activities:
    		                                       
      net income
    		-129,000,000 23,000,000 -101,000,000 -206,000,000 -759,000,000 -110,000,000 -227,000,000   188,000,000 141,000,000 97,000,000 93,000,000 182,400,000 170,800,000 82,400,000 66,500,000 45,600,000  71,100,000    82,700,000   3,800,000  26,000,000 17,400,000 4,600,000  9,800,000       
      adjustments to reconcile net income to net cash from operations:
    		                                       
      depreciation and amortization
    		113,000,000 130,000,000 126,000,000 121,000,000 112,000,000 114,000,000 106,000,000 103,000,000 99,000,000 100,000,000 99,000,000 98,000,000 81,000,000 73,000,000 140,100,000 69,100,000 187,300,000 122,500,000 60,600,000 54,700,000 66,400,000 54,600,000 52,900,000 52,600,000 51,700,000 46,800,000 39,000,000 38,700,000 36,500,000 35,500,000 35,800,000 35,100,000 34,800,000 35,200,000 35,500,000 36,200,000 34,400,000 35,200,000 35,000,000 
      goodwill impairment charges
    		 0 0 -2,000,000 689,000,000 0                                  
      non-cash foreign currency transaction (gain) loss
    		-10,000,000     -3,000,000       9,000,000  -12,000,000                         
      amortization of debt issuance costs
    		3,000,000  4,000,000 4,000,000 2,000,000  2,000,000 2,000,000 2,000,000  1,000,000 2,000,000 2,000,000                           
      impairments charges and loss/gain on sale of assets
    		4,000,000   15,000,000 -1,000,000  5,000,000 1,000,000 -2,000,000                               
      gain on sale of subsidiary
    		-17,000,000          0 0 -1,000,000                           
      stock-based compensation
    		17,000,000 16,000,000 17,000,000 16,000,000 19,000,000 0 6,000,000 10,000,000 19,000,000 12,000,000 10,000,000 11,000,000 21,000,000 12,500,000 30,100,000      6,600,000 7,500,000 10,000,000                 
      benefit from deferred income taxes
    		-5,000,000  3,000,000 17,000,000 -44,000,000   17,000,000 -4,000,000 1,000,000 12,000,000                             
      benefit from bad debts and inventory
    		39,000,000 -5,000,000 43,000,000 34,000,000 10,000,000 44,000,000 32,000,000 39,000,000 28,000,000 3,000,000 5,000,000 -1,000,000 10,000,000 1,000,000 18,400,000 7,900,000 11,400,000 9,400,000 4,100,000 1,900,000 5,500,000 2,300,000 2,800,000 2,000,000 1,400,000 -1,400,000 4,900,000 5,400,000 2,300,000 1,300,000 2,000,000 5,000,000 1,100,000 6,200,000 900,000 3,200,000 2,300,000 5,500,000 1,700,000 
      change in operating assets and liabilities:
    		                                       
      decrease in trade receivables
    		173,000,000  -35,000,000 5,000,000 160,000,000  -130,000,000 117,000,000 31,000,000   -54,000,000 185,000,000  87,600,000 143,700,000  4,300,000                      
      increase in inventories
    		-10,000,000  -15,000,000 -15,000,000 -31,000,000 -57,000,000 45,000,000 -95,000,000 -85,000,000 -35,000,000 55,000,000 -85,000,000 -63,000,000 -20,000,000 -140,300,000                         
      decrease in accounts payable
    		-10,000,000  -18,000,000 33,000,000 -73,000,000    -52,000,000         -13,300,000                      
      other assets/accrued liabilities, net—current and non-current
    		-107,000,000  -33,000,000 78,000,000 -163,000,000  -64,000,000 -26,000,000 -155,000,000  -79,000,000 -49,000,000 -165,000,000  -68,800,000 -93,400,000 -48,400,000 -49,300,000 -52,700,000                     
      net cash from operating activities
    		61,000,000 214,000,000 12,000,000 112,000,000 -70,000,000 196,000,000 -64,000,000 214,000,000 -92,000,000 69,000,000 138,000,000 69,000,000 163,000,000 134,300,000 223,700,000 149,700,000 267,600,000 145,900,000 25,200,000 87,900,000 75,300,000 43,300,000 41,200,000 103,300,000 95,200,000 92,300,000 83,700,000             
      capex
    		18,000,000 0 -8,000,000 0 21,000,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -88,800,000 -48,000,000 -43,000,000 -38,300,000 -58,800,000 -34,800,000 -40,200,000 -42,700,000             
      free cash flows
    		79,000,000 214,000,000 4,000,000 112,000,000 -49,000,000 196,000,000 -64,000,000 214,000,000 -92,000,000 69,000,000 138,000,000 69,000,000 163,000,000 134,300,000 223,700,000 149,700,000 267,600,000 145,900,000 25,200,000 -900,000 27,300,000 300,000 2,900,000 44,500,000 60,400,000 52,100,000 41,000,000             
      cash flows used in investing activities:
    		                                       
      acquisition of property, equipment, and other productive assets
    		-57,000,000  -74,000,000 -94,000,000 -84,000,000  -138,000,000 -168,000,000 -149,000,000  -148,000,000 -123,000,000 -154,000,000  -338,900,000 -149,600,000 -303,500,000 -152,200,000 -73,500,000                     
      proceeds from sale of property and equipment
    		 0 0 0 1,000,000 0 1,000,000 1,000,000 6,000,000      300,000     100,000    0 0   0 -600,000           
      proceeds from sale of subsidiary
    		23,000,000                                       
      payment for investments
    		 1,000,000 0    -1,000,000                                 
      net cash from investing activities
    		-34,000,000 -74,000,000 -74,000,000 -95,000,000 -84,000,000 -121,000,000 -110,000,000 -608,000,000 -116,000,000 -394,000,000 -191,000,000 -1,132,000,000 -167,000,000 -213,100,000 -354,400,000 -151,200,000                        
      cash flows from financing activities:
    		                                       
      proceeds from borrowing
    		    115,000,000  90,000,000 550,000,000 75,000,000    1,096,000,000 -2,600,000   1,109,100,000       0 0   0 0 322,400,000 75,000,000     0 0   
      payments related to long-term obligations
    		-5,000,000  -249,000,000 -687,000,000 -35,000,000  -144,000,000 -25,000,000 -7,000,000 -6,000,000 -8,000,000 -61,000,000 -3,000,000 -12,200,000 -54,800,000 -2,400,000 -808,900,000 -51,500,000 -3,300,000 -782,300,000 -4,600,000 -48,700,000 -454,700,000 -4,700,000 -4,800,000 -4,700,000 -4,700,000 -4,600,000 -4,700,000 -204,500,000 -4,700,000 -4,700,000 -4,600,000 -4,600,000 -4,700,000 -5,000,000 -5,500,000 -5,500,000 -863,800,000 
      financing fees paid
    		 0 0 -15,000,000 -1,000,000 0 0   0 0 0 -15,000,000 -300,000   -25,100,000       0 0    0           
      cash received, in lieu of equity, for tax-withholding obligations
    		1,000,000                                       
      exercise of stock options
    		1,000,000 0 8,000,000 0 1,000,000 0 3,000,000 0 1,000,000 5,000,000 2,000,000 11,000,000 8,000,000 15,900,000                          
      other financing activities
    		-7,000,000 -5,000,000 -4,000,000 -12,000,000 18,000,000 3,000,000 26,000,000 4,000,000 3,000,000 3,000,000 3,000,000 2,000,000 4,000,000 3,800,000 3,700,000                         
      net cash from financing activities
    		-10,000,000 -10,000,000 0 -14,000,000 98,000,000 -51,000,000 -25,000,000 523,000,000 74,000,000 1,000,000 -3,000,000 -49,000,000 1,082,000,000 -17,300,000 -7,200,000          -7,800,000 419,400,000 263,000,000             
      effect of foreign currency exchange on cash and cash equivalents
    		29,000,000  -5,000,000 17,000,000 -15,000,000  9,000,000 32,000,000 -34,000,000  -7,000,000 -8,000,000 -5,000,000                           
      net increase in cash and cash equivalents
    		46,000,000        -168,000,000    1,073,000,000                           
      cash and cash equivalents at beginning of period
    		289,000,000  0 0 280,000,000  0 0 449,000,000  0 0 896,000,000                           
      cash and cash equivalents at end of period
    		335,000,000  -67,000,000 20,000,000 209,000,000  -190,000,000 161,000,000 281,000,000  -63,000,000 -1,120,000,000 1,969,000,000                           
      supplementary cash flow information:
    		                                       
      interest paid
    		68,000,000 44,000,000 70,000,000 47,000,000 65,000,000 43,000,000 62,000,000 37,000,000 46,000,000 23,000,000 43,000,000 10,000,000 40,000,000 8,000,000 52,000,000 43,400,000 88,700,000 47,700,000 24,800,000 27,900,000 22,400,000 22,700,000 29,500,000 26,000,000 15,700,000 24,800,000 16,700,000 26,000,000 15,400,000 19,200,000 20,200,000 19,800,000 21,600,000 20,200,000 20,800,000 20,600,000 19,500,000 22,700,000 44,300,000 
      income taxes paid
    		9,000,000 -21,000,000 33,000,000 12,000,000 19,000,000 16,000,000 45,000,000 27,000,000 11,000,000 13,000,000 13,000,000 12,000,000 15,000,000 22,200,000 18,900,000 8,800,000 38,900,000 19,600,000 12,700,000 6,800,000 11,000,000 9,600,000 14,800,000 15,600,000 300,000 100,000 7,900,000 14,000,000 6,100,000 8,800,000 10,900,000 10,400,000 10,200,000 10,000,000 10,000,000 10,300,000 5,600,000 8,200,000 9,900,000 
      non-cash purchase of property, equipment, and other productive assets
    		18,000,000  -8,000,000 0 21,000,000                                   
      adjustments to reconcile net earnings to net cash from operations:
    		                                       
      amortization of debt financing costs
    		                                       
      non-cash restructuring charges
    		 0 0   0 11,000,000                                 
      impairment charges and loss/gain on sale of assets
    		 2,000,000                                      
      benefit for deferred income taxes
    		            -8,000,000   -10,600,000 5,400,000 2,700,000                      
      pension settlement charges
    		 0 9,000,000                                     
      other operating activities
    		                                       
      decrease (increase) in trade receivables
    		                                       
      decrease (increase) in inventories
    		                                       
      increase in accounts payable
    		         71,000,000 -37,000,000 9,000,000 -6,000,000 13,400,000 13,400,000  29,900,000                       
      other assets/accrued liabilities, net - current and non-current
    		                         -15,600,000 -60,500,000 33,300,000 37,000,000 0 -23,600,000         
      acquisition of property and equipment
    		                                       
      proceeds from maturity (purchases) of marketable securities
    		                                       
      settlement on sale of subsidiaries
    		           0 -3,000,000                           
      payment for acquisitions, net of cash acquired
    		     0 0   -166,000,000 -13,000,000 -994,000,000 -26,000,000 100,000 -14,800,000  -379,700,000 -10,700,000 -10,700,000 -1,163,500,000 0 0 -127,500,000 0 0    -84,200,000 1,200,000 -86,900,000         
      proceeds from borrowings
    		 140,000,000 245,000,000       0 0                             
      payments related to financing obligations
    		                                       
      dividends paid
    		         0 0 0 -4,000,000 -4,300,000 -13,000,000 -8,100,000 -28,100,000 -20,000,000 -11,900,000                     
      cash paid, in lieu of equity, for tax withholding obligation
    		                                       
      effect of foreign currency on cash
    		                       -20,300,000 9,400,000 -600,000 9,100,000 6,000,000 7,900,000 -9,900,000 900,000 -2,600,000 0 -2,600,000 -1,300,000 2,100,000 -4,800,000 -3,300,000 -13,600,000 
      net increase in cash and equivalents
    		                                       
      cash and equivalents at beginning of period
    		              953,200,000 953,200,000 345,400,000 345,400,000 345,400,000 0 0 0 410,200,000 0 0 0 288,300,000 0 0 0 131,600,000 0 0 0 151,300,000 0 0 0 74,400,000 
      cash and equivalents at end of period
    		              833,100,000 1,007,000,000 608,400,000 188,900,000 243,400,000 117,500,000 20,000,000 -58,200,000 266,100,000 18,700,000 62,000,000 -271,900,000 601,400,000 47,100,000 -14,600,000 123,700,000 132,100,000 -2,300,000 18,400,000 -35,900,000 151,400,000 35,200,000 32,000,000 20,900,000 63,200,000 
      supplementary disclosure of non-cash investing and financing activity:
    		                                       
      issuance of common stock from partial conversion of redeemable preferred stock
    		                                       
      non-cash purchase of property, equipment
    		                                       
      fiscal year ended june 30, 2024
    		                                       
      manufacturing & commercial product supply
    		              124,400,000 89,900,000 217,600,000 245,000,000 242,000,000                     
      development services & clinical supply
    		                                       
      total
    		              403,900,000 377,100,000 242,300,000 267,900,000 263,700,000                     
      inter-segment revenue elimination
    		                                       
      combined net revenue
    		                                       
      adjustments to reconcile net income to net cash from operating activities:
    		                                       
      non-cash foreign currency transaction gain
    		          0     -3,800,000                        
      proceeds from maturity of marketable securities
    		           -16,000,000 20,000,000                           
      net decrease in cash and cash equivalents
    		  -67,000,000 20,000,000 -71,000,000  -190,000,000                                 
      non-cash foreign currency transaction loss
    		   2,000,000 9,000,000   -26,000,000 27,000,000        2,500,000 5,500,000                      
      (payment) proceeds for investments
    		    -1,000,000                                   
      financing-related charges
    		          0 0 4,000,000                           
      gain on derivative instrument
    		         0 0 0 -2,000,000  -16,000,000   -1,400,000                      
      (settlement on) proceeds from sale of subsidiaries
    		         0                              
      payment made for investments
    		         2,000,000 -1,000,000 1,000,000 -4,000,000 -26,900,000 -1,000,000 -1,600,000 -2,400,000 -2,000,000 -700,000 -500,000                    
      proceeds from sale of common stock
    		             200,000 81,800,000 83,600,000 494,200,000   200,000 -200,000 0 445,500,000 0 0               
      net decrease in cash and equivalents
    		              -120,100,000                         
      note receivable from sale of blow-fill-seal business
    		                                       
      fiscal year ended june 30, 2023
    		                                       
      (benefit from) benefit from deferred income taxes
    		              -5,300,000                         
      proceeds from maturity of (purchase of) marketable securities
    		                                       
      cash paid, in lieu of equity, for tax-withholding obligations
    		          0 -5,000,000 -4,000,000  -26,400,000 -19,600,000 -25,300,000 -24,400,000 -18,100,000  -2,300,000 -5,900,000 -5,100,000                 
      proceeds from sale of marketable securities
    		       37,000,000 24,000,000                               
      proceeds from (payment for) investments
    		        3,000,000                               
      cash received (paid), in lieu of equity, for tax-withholding obligations
    		        2,000,000                               
      non-cash foreign currency transaction losses (gains)
    		                                       
      amortization and write-off of debt financing costs
    		              3,300,000 1,700,000 10,700,000 3,100,000 1,500,000 7,100,000 1,000,000 900,000 5,200,000 1,100,000                
      asset impairments charges and gain/loss on sale of assets
    		                                       
      (gain) loss on sale of subsidiary
    		             2,000,000                          
      financing related charges
    		                                       
      increase in trade receivables
    		             -184,800,000                          
      cash flows from investing activities:
    		                                       
      acquisition of property and equipment and other productive assets
    		                   -88,800,000 -48,000,000 -43,000,000 -38,300,000 -58,800,000 -34,800,000 -40,200,000 -42,700,000 -52,000,000 -33,700,000 -26,400,000 -27,700,000 -31,800,000 -25,300,000 -49,300,000 -33,200,000 -32,300,000 -37,400,000 -40,100,000 -31,200,000 
      purchases of marketable securities
    		         5,000,000    2,900,000                          
      fiscal year ended june 30, 2022
    		                                       
      development services
    		              279,500,000 287,200,000 24,700,000 22,900,000 21,700,000                     
      clinical supply services
    		                                       
      impairments charges and gain on sale of assets
    		          2,000,000                             
      impairments charges and (gain) loss on sale of assets
    		            3,000,000                           
      net change in other borrowings
    		             400,000 1,500,000 -3,900,000 -45,200,000 -5,900,000 -2,500,000 -1,900,000 -1,600,000 -400,000 -4,500,000 -500,000 -2,000,000 1,100,000 -1,700,000 100,000 -300,000 -1,300,000 -4,300,000         
      non-cash foreign currency transaction (gains) losses
    		                                       
      asset impairments charges and (gain) loss on sale of assets
    		              2,400,000                         
      proceeds from sale of subsidiaries
    		             200,000   20,800,000 20,800,000      0 0               
      proceeds from sale of preferred stock
    		                                       
      fiscal year ended june 30, 2021
    		                                       
      (gain) loss on derivative instrument
    		                                       
      prepayment for pending business acquisition
    		                 -55,100,000                      
      effect of foreign currency exchange on cash
    		              17,800,000 5,700,000 -10,500,000 -1,400,000 -6,500,000  2,300,000 -3,500,000 -700,000                 
      three months ended december 31, 2020
    		                                       
      adjustments to reconcile earnings from operations to net cash from operations:
    		                                       
      asset impairments charges and /loss on sale of assets
    		               1,800,000 2,100,000 1,500,000                      
      (gain) / loss on derivative instrument
    		               -9,000,000                        
      equity compensation
    		               18,700,000 35,500,000 26,900,000 16,600,000     6,100,000 5,600,000 8,500,000 7,000,000 4,500,000 4,600,000 4,900,000 6,900,000 2,300,000 3,400,000 2,600,000 2,500,000 2,600,000 2,100,000 2,800,000 1,500,000 
      (increase)/decrease in inventories
    		               -65,400,000                        
      increase/(decrease) in accounts payable
    		               6,600,000   -47,300,000  17,200,000 7,000,000 -18,300,000 17,000,000 15,700,000 -2,400,000 2,000,000 22,300,000 2,200,000 -13,400,000 -1,200,000 14,800,000 1,200,000 3,800,000 1,600,000 2,300,000 7,500,000 4,800,000 -26,300,000 
      net cash provided by/(used in) financing activities
    		               49,600,000             -7,300,000 109,800,000 65,900,000         
      net increase/(decrease) in cash and equivalents
    		               53,800,000 263,000,000 -156,500,000 -102,000,000 117,500,000 20,000,000 -58,200,000 -144,100,000 18,700,000 62,000,000 -271,900,000 313,100,000 47,100,000 -14,600,000 123,700,000 500,000 -2,300,000 18,400,000 -35,900,000 100,000 35,200,000 32,000,000 20,900,000 -11,200,000 
      three months ended september 30, 2020
    		                                       
      non-cash foreign currency transaction (gains)/losses
    		                                       
      asset impairments charges and (gain)/loss on sale of assets
    		                  -200,000 2,400,000 -100,000 -100,000 2,900,000                 
      reclassification of financing fees paid
    		                       0 0               
      (gain)/loss on derivative instrument
    		                  8,900,000                     
      provision/(benefit) for deferred income taxes
    		                  -600,000 -14,400,000 -600,000 -1,300,000 1,200,000 -4,900,000 4,700,000 37,400,000 -1,800,000 -2,100,000 -100,000 5,000,000 -4,100,000 -18,700,000 2,900,000 1,700,000 -1,200,000 -93,700,000 -1,300,000 -18,000,000 -7,700,000 
      (increase) in trade receivables
    		                                       
      (increase) in inventories
    		                                       
      net cash (used in) investing activities
    		                -664,800,000 -199,200,000 -84,900,000 -1,252,700,000 -48,900,000 -43,000,000 -165,800,000 -58,800,000 -34,800,000 -783,000,000 -42,700,000             
      fiscal year ended june 30, 2020
    		                                       
      call premium on debt redemption
    		                10,000,000                       
      loss on derivative instrument
    		                24,900,000                       
      decrease/(increase) in trade receivables
    		                -15,500,000  34,100,000  -29,700,000 -70,600,000 73,700,000  -71,000,000 17,600,000 87,000,000  -15,100,000 -2,500,000 43,900,000  -9,000,000 -30,000,000 59,700,000 -52,100,000 -5,200,000 -12,200,000 62,000,000 
      decrease/(increase) in inventories
    		                -54,700,000 -11,600,000 200,000  -17,100,000 -5,000,000 -21,000,000    -7,300,000  -2,300,000 -1,500,000 -16,400,000  -7,300,000 -16,000,000 -20,400,000 10,700,000 -4,700,000 -11,100,000 -14,100,000 
      net cash (used in)/provided by financing activities
    		                670,700,000 -101,800,000 -35,800,000  -8,700,000 -55,000,000 -18,800,000         -3,700,000 -6,200,000 -10,600,000 -10,300,000 -12,500,000 -13,600,000 135,700,000 86,900,000 
      three months ended march 31, 2020
    		                                       
      three months ended december 31, 2019
    		                                       
      net earnings/
    		                  100,000  -2,900,000 49,000,000 -14,400,000            8,900,000 153,400,000 30,800,000 46,000,000 -19,900,000 
      non-cash foreign currency transaction (gain)/loss
    		                  -100,000  -4,900,000 1,200,000 2,000,000  7,200,000 -1,200,000 8,300,000  9,100,000 -2,700,000 -700,000  -1,600,000 -3,500,000 -100,000  -2,400,000 -1,200,000 -11,200,000 
      three months ended september 30, 2019
    		                                       
      net revenue
    		                    -5,500,000                   
      cost of sales
    		                    -2,800,000                   
      gross margin
    		                    -2,700,000                   
      earnings from operations before income taxes
    		                                       
      income tax expense
    		                    8,600,000                   
      other assets/accrued liabilities, net — current and non-current
    		                    -700,000 -2,200,000 -55,800,000                 
      earnings from continuing operations before income taxes
    		                    -8,700,000                   
      adjustments to reconcile earnings/(loss) from operations to net cash from operations:
    		                                       
      1.
    		                                       
      adjustments to reconcile earnings from continued operations to net cash from operations:
    		                                       
      (increase)/decrease in trade receivables
    		                                       
      purchase of redeemable non-controlling interest shares
    		                                       
      asset impairments and (gain)/loss on sale of assets
    		                        200,000    1,800,000   1,900,000 -300,000 -100,000 1,200,000 900,000 300,000   
      amortization and write off of debt financing costs
    		                         1,200,000 1,300,000 1,200,000 1,300,000 3,200,000 1,100,000 1,300,000 1,100,000 1,200,000 1,100,000 1,200,000 1,000,000 1,400,000 12,400,000 
      cash paid, in lieu of equity, for tax withholding obligations
    		                         -4,000,000 -8,400,000  -2,300,000 -400,000 -100,000  -2,400,000 0 -5,600,000     
      equity offering, sale of common stock
    		                          277,800,000             
      net earnings/(loss) from discontinued operations
    		                                   -100,000 0 -200,000 400,000 
      earnings from continuing operations
    		                              4,600,000 61,900,000 9,800,000       
      adjustments to reconcile (loss)/earnings from continued operations to net cash from operations:
    		                                       
      impairments charges and (gain)/loss on sale of assets
    		                                       
      non-cash gain on acquisition
    		                                   1,300,000 0 -3,200,000 -7,000,000 
      call premium and financing fees paid
    		                                       
      net cash provided by/(used in) operating activities from continuing operations
    		                              48,300,000 33,900,000 49,900,000 26,600,000 44,900,000 77,200,000 94,300,000 40,400,000 -40,200,000 
      net cash provided by/(used in) operating activities from discontinued operations
    		                                   -100,000 0 -200,000 400,000 
      net cash provided by/(used in) operating activities
    		                             47,700,000 48,300,000 33,900,000 49,900,000 26,600,000 44,900,000 77,100,000 94,300,000 40,200,000 -39,800,000 
      payment for acquisitions
    		                                   800,000 -6,500,000 -111,600,000 -13,500,000 
      net cash provided by/(used in) investing activities
    		                             -23,900,000 -114,600,000 -29,900,000 -25,300,000 -49,300,000 -33,200,000 -31,500,000 -43,900,000 -151,700,000 -44,700,000 
      purchase of redeemable noncontrolling interest shares
    		                               0 0       
      equity contribution
    		                                       
      net cash (used in)/provided by investing activities
    		                                       
      net cash provided by/(used in) investing activities from continuing operations
    		                                  -33,200,000 -31,500,000 -43,900,000 -151,700,000 -44,700,000 
      net cash provided by/(used in) investing activities from discontinued operations
    		                                       
      net cash (used in)/provided by financing activities from continuing operations
    		                                  -10,300,000 -12,500,000 -13,600,000 135,700,000 86,900,000 
      net cash (used in)/provided by financing activities from discontinued operations
    		                                       
      reclassification of call premium payments and financing fees paid
    		                                    0 2,800,000 9,800,000 
      other accrued liabilities and operating items
    		                                13,800,000 -5,100,000 -44,800,000 12,700,000 29,500,000 -16,100,000 -76,000,000 
      net change in short-term borrowings
    		                                800,000    -1,200,000 -5,700,000 11,700,000 
      equity contribution/
    		                                    0 0 948,800,000 
      earnings/(loss) from continuing operations
    		                                  8,900,000 153,500,000 30,800,000 46,200,000 -20,300,000 
      share settlement
    		                                       
      balance at june 30, 2014
    		                                     0 891,800,000 
      additions/
    		                                       
      foreign currency translation adjustments
    		                                     -29,200,000 -32,000,000 
      balance at december 31, 2014
    		                                       
      balance at september 30, 2014
    		                                      859,800,000 
      proceeds from insurance related to long lived assets
    		                                       
      payments related to revolver credit facility fees
    		                                       
      distribution to noncontrolling interest holder
    		                                       
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.